MOLOGEN's technological advancements enhance license business potential

Strategic focus concentrated through termination of Arab joint venture

MOLOGEN AG (ISIN DE0006637200) has succeeded in considerably improving the transport and storage suitability of their therapeutics for cell-based gene therapy. The improvements were made possible by technological advancements. Due to this breakthrough, the products can now be manufactured at locations remote from the sites of their employment in therapy. This considerably increases the circle of potential licensees and thus, the scope of the rewards model. Based on these developments, MOLOGEN has decided to focus exclusively on a location-independent license model for their cell-based gene therapy. MOLOGEN expects to tap considerable potential with this approach, especially in regions with strong economic growth.

Simultaneously, MOLOGEN decided to shift their focus away from the rollout of their cell-based gene therapy through special cell- and gene therapy centers. This decision included the termination of the joint venture INMOG with their Arab partners. MOLOGEN will thus be able to cover the entire range of licensing and marketing opportunities in the Arab world. As a medium-term result, the company expects improved revenue from the region.

About MOLOGEN

MOLOGEN uses its proprietary DNA technologies to create and develop treatments for high-unmet-need illnesses. The main focuses are the unique and patented MIDGE and dSLIM technologies. Based on these platforms, MOLOGEN is developing DNA-based vaccines and therapeutics to prevent or cure a wide range of diseases.

Going public in 1998, MOLOGEN was one of the first German biotechnology companies to be floated on the stock exchange. The MOLOGEN shares are traded on the Geregelter Markt in Frankfurt.

Disclaimer concerning prognoses

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.

back to the overview